Literature DB >> 29424898

Increased expression of miR-552 acts as a potential predictor biomarker for poor prognosis of colorectal cancer.

N Wang1, W Liu.   

Abstract

OBJECTIVE: MiR-552 has recently been identified to be involved in tumorigenesis of colorectal cancer (CRC). The aim of this study was to determine if miR-552 could serve as a prognosis indicator for patients with CRC. PATIENTS AND METHODS: MiR-552 expression levels were detected in 183 pairs of primary CRC and their matched non-tumor tissues by qPCR. The association between miR-552 expression and clinicopathological parameters was analyzed. The survival curves were calculated by the Kaplan-Meier method. Univariate and multivariate analyses were performed to explore the prognostic significance of miR-552 expression.
RESULTS: We found that miR-552 expression was upregulated in CRC tumor tissues compared to their adjacent normal tissues (p < 0.01). Increased miR-552 expression was significantly associated with histological grade (p = 0.000), lymph nodes metastasis (p = 0.022) and TNM stage (p = 0.002). In addition, the patients with high miR-552 expression had a significantly worse 5-year overall survival rate than those with low miR-552 expression (p = 0.0036). Furthermore, according to univariate and multivariate analysis, elevated miR-552 was confirmed to be an independent prognostic factor for worse survival.
CONCLUSIONS: The current results demonstrated that high miR-552 expression was associated with poor outcomes in patients with CRC. MiR-552 may be a potential prognostic biomarker and therapeutic target in CRC patients.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29424898     DOI: 10.26355/eurrev_201801_14189

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

1.  miR-552 promotes laryngocarcinoma cells proliferation and metastasis by targeting p53 pathway.

Authors:  Jia Gu; Tao Han; Lei Sun; Ai-Hui Yan; Xue-Jun Jiang
Journal:  Cell Cycle       Date:  2020-04-01       Impact factor: 4.534

2.  Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.

Authors:  Igor Lopes Dos Santos; Karlla Greick Batista Dias Penna; Megmar Aparecida Dos Santos Carneiro; Larisse Silva Dalla Libera; Jéssica Enocencio Porto Ramos; Vera Aparecida Saddi
Journal:  Mol Biol Rep       Date:  2021-02-17       Impact factor: 2.316

3.  Circular RNA SMARCA5 functions as an anti-tumor candidate in colon cancer by sponging microRNA-552.

Authors:  Shiwei Yang; Shanyu Gao; Tongming Liu; Junning Liu; Xia Zheng; Zhi Li
Journal:  Cell Cycle       Date:  2021-03-22       Impact factor: 4.534

4.  Study on miRNAs in Pan-Cancer of the Digestive Tract Based on the Illumina HiSeq System Data Sequencing.

Authors:  Chun-Hui Lai; Xu-Zhi Liang; Xiu-Yun Liang; Sheng-Jun Ma; Jun-Guo Li; Ming-Fang Shi; Xu Zhu; Hui-Hua Lan; Jiang-Hui Zeng
Journal:  Biomed Res Int       Date:  2019-10-15       Impact factor: 3.411

5.  MicroRNA-552 expression in colorectal cancer and its clinicopathological significance.

Authors:  Joon Im; Soo Kyung Nam; Hye Seung Lee
Journal:  J Pathol Transl Med       Date:  2021-02-19

6.  MicroRNA-552 Accelerates the Progression of Gastric Cancer by Targeting FOXO1 and Regulating PI3K/AKT Pathway.

Authors:  Yuguo Zhao; Jianwen Zhang; Wenbin Yang; Zhao Yang; Kaikai Zhou
Journal:  J Oncol       Date:  2021-05-04       Impact factor: 4.375

7.  miR-552 Regulates Liver Tumor-Initiating Cell Expansion and Sorafenib Resistance.

Authors:  Tao Han; Yue Zhang; Xiaodan Yang; Lei Han; Hengyu Li; Tingsong Chen; Zhendong Zheng
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-15       Impact factor: 8.886

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.